Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
11-deoxycorticosterone + reduced adrenodoxin + O2
corticosterone + oxidized adrenodoxin + H2O
11-deoxycortisol + oxidized adrenodoxin + H2O
cortisol + reduced adrenodoxin + O2
Substrates: -
Products: -
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + oxidized adrenal ferredoxin + H2O
11-deoxycortisol + reduced adrenodoxin + O2
cortisol + oxidized adrenodoxin + H2O
Substrates: -
Products: -
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + oxidized adrenal ferredoxin + H2O
Substrates: -
Products: -
?
androstendione + reduced adrenodoxin + O2
? + oxidized adrenodoxin + H2O
Substrates: low activity with isozyme CYP11B1
Products: -
?
corticosterone + reduced adrenodoxin + O2
18-hydroxycorticosterone + oxidized adrenodoxin + H2O
Substrates: -
Products: -
?
deoxycorticosterone + oxidized adrenodoxin + H2O
corticosterone + reduced adrenodoxin + O2
Substrates: -
Products: -
?
progesterone + reduced adrenodoxin + O2
11beta-hydroxyprogesterone + oxidized adrenodoxin + H2O
Substrates: low activity with isozyme CYP11B1
Products: -
?
testosterone + reduced adrenodoxin + O2
11-hydroxytestosterone + oxidized adrenodoxin + H2O
Substrates: low activity with isozyme CYP11B1
Products: -
?
11-deoxycorticosterone + adrenal ferredoxin + H2O
corticosterone + reduced adrenal ferredoxin + O2
-
Substrates: -
Products: -
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
?
Substrates: -
Products: -
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
corticosterone + oxidized adrenal ferredoxin + H2O
-
Substrates: 11beta-hydroxylation
Products: -
?
11-deoxycorticosterone + reduced adrenodoxin + O2
corticosterone + oxidized adrenodoxin + H2O
11-deoxycortisol + adrenal ferredoxin + H2O
cortisol + reduced adrenal ferredoxin + O2
-
Substrates: -
Products: -
?
11-deoxycortisol + NADPH + O2
cortisol + NADP+ + H2O
-
Substrates: -
Products: -
?
11-deoxycortisol + oxidized adrenodoxin + H2O
cortisol + reduced adrenodoxin + O2
Substrates: -
Products: -
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + oxidized adrenal ferredoxin + H2O
11-deoxycortisol + reduced adrenodoxin + O2
cortisol + oxidized adrenodoxin + H2O
Substrates: -
Products: -
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + oxidized adrenal ferredoxin + H2O
18-hydroxycorticosterone + reduced adrenodoxin + O2
aldosterone + oxidized adrenodoxin + H2O
Substrates: -
Products: -
?
18-hydroxycorticosterone + reduced ferredoxin + O2
aldosterone + ferredoxin + H2O
a steroid + reduced adrenodoxin + O2
an 11beta-hydroxysteroid + oxidized adrenodoxin + H2O
-
Substrates: -
Products: -
?
androstendione + reduced adrenodoxin + O2
? + oxidized adrenodoxin + H2O
Substrates: low activity with isozyme CYP11B2
Products: -
?
corticosterone + reduced adrenal ferredoxin + O2
11-deoxycorticosterone + adrenal ferredoxin + ?
-
Substrates: -
Products: -
?
corticosterone + reduced adrenodoxin + O2
18-hydroxycorticosterone + oxidized adrenodoxin + H2O
cortisol + reduced adrenal ferredoxin + O2
11-deoxycortisol + adrenal ferredoxin + ?
deoxycorticosterone + oxidized adrenodoxin + H2O
corticosterone + reduced adrenodoxin + O2
Substrates: -
Products: -
?
progesterone + reduced adrenodoxin + O2
11beta-hydroxyprogesterone + oxidized adrenodoxin + H2O
Substrates: low activity with isozyme CYP11B2
Products: -
?
testosterone + reduced adrenodoxin + O2
11-hydroxytestosterone + oxidized adrenodoxin + H2O
Substrates: low activity with isozyme CYP11B2
Products: -
?
additional information
?
-
11-deoxycorticosterone + reduced adrenodoxin + O2
corticosterone + oxidized adrenodoxin + H2O
Substrates: -
Products: -
?
11-deoxycorticosterone + reduced adrenodoxin + O2
corticosterone + oxidized adrenodoxin + H2O
Substrates: i.e. 21-hydroxyprogesterone
Products: -
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + oxidized adrenal ferredoxin + H2O
Substrates: -
Products: -
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + oxidized adrenal ferredoxin + H2O
Substrates: CYP11B1
Products: -
?
11-deoxycorticosterone + reduced adrenodoxin + O2
corticosterone + oxidized adrenodoxin + H2O
Substrates: -
Products: -
?
11-deoxycorticosterone + reduced adrenodoxin + O2
corticosterone + oxidized adrenodoxin + H2O
Substrates: -
Products: -
?
11-deoxycorticosterone + reduced adrenodoxin + O2
corticosterone + oxidized adrenodoxin + H2O
Substrates: i.e. 21-hydroxyprogesterone
Products: -
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + oxidized adrenal ferredoxin + H2O
-
Substrates: -
Products: -
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + oxidized adrenal ferredoxin + H2O
-
Substrates: 11beta-hydroxylation
Products: -
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + oxidized adrenal ferredoxin + H2O
-
Substrates: CYP11B1
Products: -
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + oxidized adrenal ferredoxin + H2O
-
Substrates: deficiency of steroid 11-hydroxylase CYP11B1 due to mutations in the CYP11B1 gene causes congenital adrenal hyperplasia, a group of autosomal recessive disorders, overview
Products: -
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + oxidized adrenal ferredoxin + H2O
-
Substrates: -
Products: -
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + oxidized adrenal ferredoxin + H2O
-
Substrates: CYP11B2
Products: -
?
18-hydroxycorticosterone + reduced ferredoxin + O2
aldosterone + ferredoxin + H2O
-
Substrates: -
Products: -
?
18-hydroxycorticosterone + reduced ferredoxin + O2
aldosterone + ferredoxin + H2O
-
Substrates: aldosterone is one of the main effectors of the reninĀangiotensinĀaldosterone system, RAAS, regulating salt and water homeostasis and thereby also blood pressure
Products: -
?
corticosterone + reduced adrenodoxin + O2
18-hydroxycorticosterone + oxidized adrenodoxin + H2O
Substrates: -
Products: -
?
corticosterone + reduced adrenodoxin + O2
18-hydroxycorticosterone + oxidized adrenodoxin + H2O
Substrates: -
Products: -
?
cortisol + reduced adrenal ferredoxin + O2
11-deoxycortisol + adrenal ferredoxin + ?
-
Substrates: -
Products: -
?
cortisol + reduced adrenal ferredoxin + O2
11-deoxycortisol + adrenal ferredoxin + ?
-
Substrates: in the adrenal zona fasciculata
Products: -
?
additional information
?
-
Substrates: enzyme is responsible for the final step of aldosterone synthesis. It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone
Products: -
?
additional information
?
-
Substrates: enzyme is responsible for the final step of aldosterone synthesis. It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone
Products: -
?
additional information
?
-
-
Substrates: enzyme is responsible for the final step of aldosterone synthesis. It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone
Products: -
?
additional information
?
-
Substrates: substrate specificties of isozymes CYP11B2 and CYP11B1, overview. No or poor activity of CYP11B1 with cortisol, 18-hydroxycorticosterone, 11-dehydrocorticosterone, 21-hydroxypregnenolone, and 11beta-hydroxyprogesterone
Products: -
?
additional information
?
-
Substrates: substrate specificties of isozymes CYP11B2 and CYP11B1, overview. No or poor activity of CYP11B1 with cortisol, 18-hydroxycorticosterone, 11-dehydrocorticosterone, 21-hydroxypregnenolone, and 11beta-hydroxyprogesterone
Products: -
?
additional information
?
-
-
Substrates: substrate specificties of isozymes CYP11B2 and CYP11B1, overview. No or poor activity of CYP11B1 with cortisol, 18-hydroxycorticosterone, 11-dehydrocorticosterone, 21-hydroxypregnenolone, and 11beta-hydroxyprogesterone
Products: -
?
additional information
?
-
-
Substrates: -344T/C polymorphism is associated with a clinically relevant phenotype for diabetic nephropathy such as hypertension
Products: -
?
additional information
?
-
-
Substrates: CYP11B2-CYP11B1 haplotypes associate with decreased 11beta-hydroxylase activity, overview
Products: -
?
additional information
?
-
-
Substrates: effects of enzyme inhibition of steroid biosynthesis and mineralcorticoid formation, overview
Products: -
?
additional information
?
-
-
Substrates: enzyme deficiency is a cause for congenital adrenal hyperplasia, overview
Products: -
?
additional information
?
-
-
Substrates: genetic variation at the locus encompassing 11-beta hydroxylase and aldosterone synthase accounts for heritability in cortisol precursor 11-deoxycortisol urinary metabolite excretion, overview
Products: -
?
additional information
?
-
-
Substrates: non-classical enzyme deficiency causes mild androgen excess, hirsutism, precocious adrenarche and accelerated growth in children, missense mutations are responsible for non-classical adrenal hyperplasia in children, overview
Products: -
?
additional information
?
-
-
Substrates: variation of 344 C/T and intron 2 in the CYP11B2 gene, encoding aldosterone synthase, is associated with CYP11B1 deficiency due to variations of gene CYP11B1 at positions 1889 and 1859 and disequiliibrium with CYP11B2, overview
Products: -
?
additional information
?
-
-
Substrates: 11-beta-hydroxylase deficiency, i.e. 11betaOHD is caused by CYP11B1 gene defects and leads to congenital adrenal hyperplasia associated with hypertension, overview
Products: -
?
additional information
?
-
-
Substrates: 11beta-hydroxylase deficiency is the second most common form of congenital adrenal hyperplasia after 21-hydroxylase deficiency, overview
Products: -
?
additional information
?
-
-
Substrates: congenital adrenal hyperplasia due to steroid 11beta-hydroxylase deficiency is a genetic disorder of steroidogenesis, transmitted as an autosomal recessive trait. It is associated with low renin hypertension, hypokalemia, hyperandrogenemia and genital ambiguity in affected females, overview
Products: -
?
additional information
?
-
-
Substrates: deficiency of 11beta-hydroxylase results in decreased synthesis of cortisol and glucocorticoids, and thus causes weakened depressive feedback ofACTH and increased synthesis of ACTH in pituitary, which leads to production of more cortisol precursor in zona fasciculata, enzyme regulation, overview
Products: -
?
additional information
?
-
-
Substrates: enzyme deficiency leads to hypokalemia and further, when under-treated, to rhabdomyolysis, overview
Products: -
?
additional information
?
-
-
Substrates: the enzyme is regulated by adrenocorticotrophic hormone, ACTH
Products: -
?
additional information
?
-
-
Substrates: the polymorphism genotype of gene CYP11B2, encoding aldosterone synthase, affects the activity of the 11beta-hydroxylase, encoded by gene CYP11B1, overview
Products: -
?
additional information
?
-
-
Substrates: the recombinant enzyme is capable of hydroxylating its substrates at position 11-beta
Products: -
?
additional information
?
-
Substrates: enzyme is responsible for the final step of aldosterone synthesis. It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone
Products: -
?
additional information
?
-
Substrates: enzyme is responsible for the final step of aldosterone synthesis. It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone
Products: -
?
additional information
?
-
-
Substrates: enzyme is responsible for the final step of aldosterone synthesis. It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone
Products: -
?
additional information
?
-
-
Substrates: CYP11B2 hydroxylates 18-hydroxycorticosterone
Products: -
?
additional information
?
-
-
Substrates: steroid 11beta-hydroxylase converts 11-deoxycortisol and 11-deoxycorticosterone to cortisol and corticosterone, respectively
Products: -
?
additional information
?
-
Substrates: bifunctional enzyme catalyzing the biosynthesis of aldosterone by successive 11beta- and 18-hydroxylation followed by an 18-oxidation of 11-deoxycorticosterone
Products: -
?
additional information
?
-
-
Substrates: bifunctional enzyme catalyzing the biosynthesis of aldosterone by successive 11beta- and 18-hydroxylation followed by an 18-oxidation of 11-deoxycorticosterone
Products: -
?
additional information
?
-
-
Substrates: N-terminally unprocessed enzyme has 2fold more activity than the mature physiological enzyme
Products: -
?
additional information
?
-
Substrates: aldosterone synthase shows high 11beta-hydroxylase activity toward both gluco- and mineralocorticoid formation, and additional 18-oxidase activity, substrate specificties of isozymes CYP11B2 and CYP11B1, overview. No oxidation activity of CYP11B2 with 18-hydroxycorticosterone, 11-dehydrocorticosterone, 21-hydroxypregnenolone, and poor activity with cortisol
Products: -
?
additional information
?
-
Substrates: aldosterone synthase shows high 11beta-hydroxylase activity toward both gluco- and mineralocorticoid formation, and additional 18-oxidase activity, substrate specificties of isozymes CYP11B2 and CYP11B1, overview. No oxidation activity of CYP11B2 with 18-hydroxycorticosterone, 11-dehydrocorticosterone, 21-hydroxypregnenolone, and poor activity with cortisol
Products: -
?
additional information
?
-
-
Substrates: aldosterone synthase shows high 11beta-hydroxylase activity toward both gluco- and mineralocorticoid formation, and additional 18-oxidase activity, substrate specificties of isozymes CYP11B2 and CYP11B1, overview. No oxidation activity of CYP11B2 with 18-hydroxycorticosterone, 11-dehydrocorticosterone, 21-hydroxypregnenolone, and poor activity with cortisol
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
11-deoxycorticosterone + reduced adrenodoxin + O2
corticosterone + oxidized adrenodoxin + H2O
Substrates: -
Products: -
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + oxidized adrenal ferredoxin + H2O
Substrates: -
Products: -
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + oxidized adrenal ferredoxin + H2O
Substrates: -
Products: -
?
corticosterone + reduced adrenodoxin + O2
18-hydroxycorticosterone + oxidized adrenodoxin + H2O
Substrates: -
Products: -
?
11-deoxycorticosterone + reduced adrenodoxin + O2
corticosterone + oxidized adrenodoxin + H2O
11-deoxycortisol + adrenal ferredoxin + H2O
cortisol + reduced adrenal ferredoxin + O2
-
Substrates: -
Products: -
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + oxidized adrenal ferredoxin + H2O
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + oxidized adrenal ferredoxin + H2O
18-hydroxycorticosterone + reduced adrenodoxin + O2
aldosterone + oxidized adrenodoxin + H2O
Substrates: -
Products: -
?
18-hydroxycorticosterone + reduced ferredoxin + O2
aldosterone + ferredoxin + H2O
-
Substrates: aldosterone is one of the main effectors of the reninĀangiotensinĀaldosterone system, RAAS, regulating salt and water homeostasis and thereby also blood pressure
Products: -
?
corticosterone + reduced adrenal ferredoxin + O2
11-deoxycorticosterone + adrenal ferredoxin + ?
-
Substrates: -
Products: -
?
corticosterone + reduced adrenodoxin + O2
18-hydroxycorticosterone + oxidized adrenodoxin + H2O
cortisol + reduced adrenal ferredoxin + O2
11-deoxycortisol + adrenal ferredoxin + ?
-
Substrates: in the adrenal zona fasciculata
Products: -
?
additional information
?
-
11-deoxycorticosterone + reduced adrenodoxin + O2
corticosterone + oxidized adrenodoxin + H2O
Substrates: -
Products: -
?
11-deoxycorticosterone + reduced adrenodoxin + O2
corticosterone + oxidized adrenodoxin + H2O
Substrates: -
Products: -
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + oxidized adrenal ferredoxin + H2O
-
Substrates: -
Products: -
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + oxidized adrenal ferredoxin + H2O
-
Substrates: CYP11B1
Products: -
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + oxidized adrenal ferredoxin + H2O
-
Substrates: deficiency of steroid 11-hydroxylase CYP11B1 due to mutations in the CYP11B1 gene causes congenital adrenal hyperplasia, a group of autosomal recessive disorders, overview
Products: -
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + oxidized adrenal ferredoxin + H2O
-
Substrates: -
Products: -
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + oxidized adrenal ferredoxin + H2O
-
Substrates: CYP11B2
Products: -
?
corticosterone + reduced adrenodoxin + O2
18-hydroxycorticosterone + oxidized adrenodoxin + H2O
Substrates: -
Products: -
?
corticosterone + reduced adrenodoxin + O2
18-hydroxycorticosterone + oxidized adrenodoxin + H2O
Substrates: -
Products: -
?
additional information
?
-
Substrates: enzyme is responsible for the final step of aldosterone synthesis. It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone
Products: -
?
additional information
?
-
Substrates: enzyme is responsible for the final step of aldosterone synthesis. It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone
Products: -
?
additional information
?
-
-
Substrates: enzyme is responsible for the final step of aldosterone synthesis. It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone
Products: -
?
additional information
?
-
-
Substrates: -344T/C polymorphism is associated with a clinically relevant phenotype for diabetic nephropathy such as hypertension
Products: -
?
additional information
?
-
-
Substrates: CYP11B2-CYP11B1 haplotypes associate with decreased 11beta-hydroxylase activity, overview
Products: -
?
additional information
?
-
-
Substrates: effects of enzyme inhibition of steroid biosynthesis and mineralcorticoid formation, overview
Products: -
?
additional information
?
-
-
Substrates: enzyme deficiency is a cause for congenital adrenal hyperplasia, overview
Products: -
?
additional information
?
-
-
Substrates: genetic variation at the locus encompassing 11-beta hydroxylase and aldosterone synthase accounts for heritability in cortisol precursor 11-deoxycortisol urinary metabolite excretion, overview
Products: -
?
additional information
?
-
-
Substrates: non-classical enzyme deficiency causes mild androgen excess, hirsutism, precocious adrenarche and accelerated growth in children, missense mutations are responsible for non-classical adrenal hyperplasia in children, overview
Products: -
?
additional information
?
-
-
Substrates: variation of 344 C/T and intron 2 in the CYP11B2 gene, encoding aldosterone synthase, is associated with CYP11B1 deficiency due to variations of gene CYP11B1 at positions 1889 and 1859 and disequiliibrium with CYP11B2, overview
Products: -
?
additional information
?
-
-
Substrates: 11-beta-hydroxylase deficiency, i.e. 11betaOHD is caused by CYP11B1 gene defects and leads to congenital adrenal hyperplasia associated with hypertension, overview
Products: -
?
additional information
?
-
-
Substrates: 11beta-hydroxylase deficiency is the second most common form of congenital adrenal hyperplasia after 21-hydroxylase deficiency, overview
Products: -
?
additional information
?
-
-
Substrates: congenital adrenal hyperplasia due to steroid 11beta-hydroxylase deficiency is a genetic disorder of steroidogenesis, transmitted as an autosomal recessive trait. It is associated with low renin hypertension, hypokalemia, hyperandrogenemia and genital ambiguity in affected females, overview
Products: -
?
additional information
?
-
-
Substrates: deficiency of 11beta-hydroxylase results in decreased synthesis of cortisol and glucocorticoids, and thus causes weakened depressive feedback ofACTH and increased synthesis of ACTH in pituitary, which leads to production of more cortisol precursor in zona fasciculata, enzyme regulation, overview
Products: -
?
additional information
?
-
-
Substrates: enzyme deficiency leads to hypokalemia and further, when under-treated, to rhabdomyolysis, overview
Products: -
?
additional information
?
-
-
Substrates: the enzyme is regulated by adrenocorticotrophic hormone, ACTH
Products: -
?
additional information
?
-
-
Substrates: the polymorphism genotype of gene CYP11B2, encoding aldosterone synthase, affects the activity of the 11beta-hydroxylase, encoded by gene CYP11B1, overview
Products: -
?
additional information
?
-
Substrates: enzyme is responsible for the final step of aldosterone synthesis. It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone
Products: -
?
additional information
?
-
Substrates: enzyme is responsible for the final step of aldosterone synthesis. It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone
Products: -
?
additional information
?
-
-
Substrates: enzyme is responsible for the final step of aldosterone synthesis. It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone
Products: -
?
additional information
?
-
-
Substrates: CYP11B2 hydroxylates 18-hydroxycorticosterone
Products: -
?
additional information
?
-
-
Substrates: steroid 11beta-hydroxylase converts 11-deoxycortisol and 11-deoxycorticosterone to cortisol and corticosterone, respectively
Products: -
?
additional information
?
-
Substrates: bifunctional enzyme catalyzing the biosynthesis of aldosterone by successive 11beta- and 18-hydroxylation followed by an 18-oxidation of 11-deoxycorticosterone
Products: -
?
additional information
?
-
-
Substrates: bifunctional enzyme catalyzing the biosynthesis of aldosterone by successive 11beta- and 18-hydroxylation followed by an 18-oxidation of 11-deoxycorticosterone
Products: -
?
additional information
?
-
-
Substrates: N-terminally unprocessed enzyme has 2fold more activity than the mature physiological enzyme
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(R)-4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile
FAD286, CYP11B2 inhibitor, inhibited CYP11B2 and CYP11B1 activities
(1R)-2-[2-[(1S)-1-(4-chlorophenyl)ethyl]-3,3-dioxido-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazin-4-yl]-1-phenylethanol
-
-
(1S)-2-[2-[(1S)-1-(4-chlorophenyl)ethyl]-3,3-dioxido-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazin-4-yl]-1-phenylethanol
-
-
(5Z)-5-(1H-imidazol-5-ylmethylene)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile
-
50% inhibition at 0.0069 mM, selective for CYP11B1
(R)-4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile
FAD286
1-(1H-inden-2-yl)-1H-imidazole
-
CYP11B2 IC50: 448 nM, no inhibition of CYP11B1, recombinant enzymes
1-(3,4-dihydronaphthalen-2-yl)-1H-imidazole
-
CYP11B1 IC50: 639 nM, CYP11B2 IC50: 334 nM, recombinant enzymes
1-(3-bromobenzyl)-1H-imidazole
-
-
1-(3-chlorobenzyl)-1H-imidazole
-
-
1-(3-cyanobenzyl)-1H-imidazole
-
-
1-(3-fluorobenzyl)-1H-imidazole
-
-
1-(4-aminobenzyl)-1H-imidazole
-
-
1-(4-bromobenzyl)-1H-imidazole
-
-
1-(4-bromobenzyl)-5-phenyl-1H-imidazole
-
-
1-(4-chlorobenzyl)-1H-imidazole
-
-
1-(4-chlorobenzyl)-5-phenyl-1H-imidazole
-
-
1-(4-cyanobenzyl)-1H-imidazole
-
-
1-(4-cyanobenzyl)-5-(2-fluorophenyl)-1H-imidazole
-
-
1-(4-cyanobenzyl)-5-(2-methylphenyl)-1H-imidazole
-
-
1-(4-cyanobenzyl)-5-(3-fluorophenyl)-1H-imidazole
-
-
1-(4-cyanobenzyl)-5-(3-methylphenyl)-1H-imidazole
-
-
1-(4-cyanobenzyl)-5-(4-fluorophenyl)-1H-imidazole
-
-
1-(4-cyanobenzyl)-5-(4-methylphenyl)-1H-imidazole
-
-
1-(4-cyanobenzyl)-5-(4-pyridyl)-1H-imidazole
-
-
1-(4-cyanobenzyl)-5-(methyl carboxylate)-1H-imidazole
-
-
1-(4-cyanobenzyl)-5-(methylene-acetate)-1H-imidazole
-
-
1-(4-cyanobenzyl)-5-bromo-1H-imidazole
-
-
1-(4-cyanobenzyl)-5-formyl-1H-imidazole
-
-
1-(4-cyanobenzyl)-5-hydroxymethyl-1H-imidazole
-
-
1-(4-cyanobenzyl)-5-methyl-1H-imidazole
-
-
1-(4-cyanobenzyl)-5-phenyl-1H-imidazole
-
-
1-(4-fluorobenzyl)-1H-imidazole
-
-
1-(4-fluorobenzyl)-5-phenyl-1H-imidazole
-
-
1-(4-methoxybenzyl)-5-phenyl-1H-imidazole
-
-
1-(6-methoxy-3,4-dihydronaphthalen-2-yl)-1H-imidazole
-
CYP11B1 IC50: 763 nM, CYP11B2 IC50: 411 nM, recombinant enzymes
1-benzyl-5-phenyl-1H-imidazole
-
-
2,3-dichloro-N-(pyridin-3-yl)benzamide
-
51% inhibition of CYP11B2 at 0.5 mM, no inhibition of CYP11B22
2,4,5-trifluoro-N-(pyridin-3-yl)benzamide
-
70% inhibition of CYP11B2 at 0.5 mM, no inhibition of CYP11B23
2-(4-chlorobenzyl)-4-(2-methylpropyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
2-(4-fluorobenzyl)-4-(2-methylpropyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
2-benzyl-4-(2-methylpropyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
2-fluoro-N-(pyridin-3-yl)benzamide
-
34% inhibition of CYP11B2 at 0.5 mM, no inhibition of CYP11B19
2-[(1R)-1-(4-chlorophenyl)ethyl]-4-(2-methylpropyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
2-[(1S)-1-(4-chlorophenyl)ethyl]-4-(2-methylpropyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
2-[(1S)-1-(4-chlorophenyl)ethyl]-4-(3-methoxy-2-methylpropyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
2-[(1S)-1-(4-chlorophenyl)ethyl]-4-(cyclopropylmethyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
2-[(1S)-1-(4-chlorophenyl)ethyl]-4-[(3-methyloxetan-3-yl)methyl]-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
2-[(1S)-1-(4-chlorophenyl)ethyl]-4-[(propan-2-yloxy)methyl]-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
3,4-difluoro-N-(pyridin-3-yl)benzamide
-
83% inhibition of CYP11B2 at 0.5 mM, 6% inhibition of CYP11B20
3,4-dimethoxy-N-(pyridin-3-yl)benzamide
-
-
3-(1-benzyl-1H-imidazol-5-yl)-1-propanol
-
-
3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine
-
CYP11B1 IC50: 2117 nM, CYP11B2 IC50: 30 nM, recombinant enzymes
3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine
-
CYP11B1 IC50: 1268 nM, CYP11B2 IC50: 7 nM, recombinant enzymes
3-(1H-imidazol-1-ylmethyl)aniline
-
-